Cargando…

Activated Clotting Time (ACT) for Monitoring of Low-Dose Heparin: Performance Characteristics in Healthy Adults and Critically Ill Patients

Dose adjustment of unfractionated heparin (UFH) anticoagulation is an important factor to reduce hemorrhagic events. High doses of heparin can be monitored by Activated Clotting Time (ACT). Because of limited information about the monitoring of low-dose heparin we assessed monitoring by ACT, aPTT an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wehner, Johannes E., Boehne, Martin, David, Sascha, Brand, Korbinian, Tiede, Andreas, Bikker, Rolf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758671/ https://www.ncbi.nlm.nih.gov/pubmed/33350327 http://dx.doi.org/10.1177/1076029620975494

Ejemplares similares

Continuation of therapeutic dose heparin for critically ill patients with COVID-19
por: Bradbury, Charlotte A., et al.
Publicado: (2023)

Use of activated clotting time to monitor anticoagulation in patients receiving unfractionated heparin on renal replacement therapy
por: Bidwai, A, et al.
Publicado: (2011)

An Antithrombin-Heparin Complex Increases the Anticoagulant Activity of Fibrin Clots
por: Smith, Lesley J., et al.
Publicado: (2008)

Inline filtration reduces the incidence of systemic inflammatory response syndrome in critically ill children
por: Jack, T, et al.
Publicado: (2009)

Dialysis circuit clotting in critically ill patients with COVID-19 infection
por: Khoo, Benjamin Zhi En, et al.
Publicado: (2021)

Continuous intra-gastral monitoring of intra-abdominal pressure in critically ill children: a validation study
por: Kaussen, T., et al.
Publicado: (2021)

EFFECT OF HEPARIN AND BIVALIRUDIN ON THE KINETICS OF CLOT FORMATION: VISCOELASTIC COAGULATION TESTING
por: Hasija, Suruchi, et al.
Publicado: (2017)

TNF Tolerance in Monocytes and Macrophages: Characteristics and Molecular Mechanisms
por: Huber, René, et al.
Publicado: (2017)

Laboratory Assessment of Unfractionated Heparin (UFH) with Activated Clotting Time (ACT) and Anti-Xa Activity during Peripheral Arterial Angiographic Procedure
por: Helin, Tuukka, et al.
Publicado: (2023)

Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients
por: Volteas, Panagiotis, et al.
Publicado: (2022)

Activated Clotting Time Level with Weight Based Heparin Dosing During Percutaneous Coronary Intervention and its Determinant Factors
por: Soleimannejad, Majid, et al.
Publicado: (2014)

Heparin thromboprophylaxis in critically ill patients: Is it really changing outcome?
por: Gurjar, Mohan
Publicado: (2014)

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19
Publicado: (2021)

CRITICALLY ILL COVID-19 PATIENTS AND THERAPEUTIC ANTICOAGULATION WITH HEPARIN
por: Vu, Michael, et al.
Publicado: (2022)

Differences in activated clotting time and total unfractionated heparin dose during pulmonary vein isolation in patients on different anticoagulation therapy
por: Zeljkovic, Ivan, et al.
Publicado: (2021)

Fractal analysis: a new biomarker for determining clot characteristics in critically ill patients
por: Davies, GR, et al.
Publicado: (2012)

Monitoring of different factor VIII replacement products using a factor VIII one‐stage clotting assay on cobas t 511/711 analysers
por: Ketteler, Carolin, et al.
Publicado: (2021)

Measuring the anticoagulant effect of low molecular weight heparins in the critically ill
por: Crowther, Mark, et al.
Publicado: (2006)

Incidence and clinical relevance of heparin-induced antibodies in critically ill patients
por: Grigoriou, P, et al.
Publicado: (2004)

Modulation of fibrin clot formation by human serum amyloid P component (SAP) and heparin
Publicado: (1983)

Comparison of digoxin concentration in plastic serum tubes with clot activator and heparinized plasma tubes
por: Dukić, Lora, et al.
Publicado: (2014)

A Blinded Randomized Trial Comparing Standard Activated Clotting Time Heparin Management to High Target Active Clotting Time and Individualized Hepcon HMS Heparin Management in Cardiopulmonary Bypass Cardiac Surgical Patients
por: Nuttall, Gregory A., et al.
Publicado: (2021)

Comparison of heparin dosing based on actual body weight in non-obese, obese and morbidly obese critically ill patients
por: Gerlach, Anthony T, et al.
Publicado: (2013)

PREVENTion of CLots in Orthopaedic Trauma (PREVENT CLOT): a randomised pragmatic trial protocol comparing aspirin versus low-molecular-weight heparin for blood clot prevention in orthopaedic trauma patients
por: O'Toole, Robert V, et al.
Publicado: (2021)

Clotting abnormalities in critically ill COVID-19 patients are inconsistent with overt disseminated intravascular coagulation
por: Paparella, Domenico, et al.
Publicado: (2020)

Activation of GSK3 Prevents Termination of TNF-Induced Signaling
por: Welz, Bastian, et al.
Publicado: (2021)

Bivalirudin or heparin: which anticoagulation strategy for critically ill cardiac surgery patients?
por: Pappalardo, F, et al.
Publicado: (2014)

Heparin-Binding Protein in Critically Ill Children With Severe Community-Acquired Pneumonia
por: Huang, Caizhi, et al.
Publicado: (2021)

Use of insulin and heparin in the management of severe hypertriglyceridemia in a critically ill patient
por: Arranz, Natàlia, et al.
Publicado: (2022)

The evolution of clot strength in critically-ill COVID-19 patients: a prospective observational thromboelastography study
por: Neethling, Colette, et al.
Publicado: (2021)

The evolution of clot strength in critically ill COVID-19 patients: a prospective observational thromboelastography study
por: Muzaffar, Syed Nabeel, et al.
Publicado: (2022)

Comparison of the New Viscoelastic Coagulation Analyzer ClotPro® With ROTEM® Delta and Conventional Coagulation Tests in Critically Ill Patients With COVID-19
por: Infanger, Lukas, et al.
Publicado: (2021)

To Clot or Not to Clot: Is That the Question?
por: Favaloro, Emmanuel J.
Publicado: (2023)

A low dose heparinized saline protocol is associated with improved duration of arterial line patency in critically ill COVID-19 patients
por: Maurer, Lydia R., et al.
Publicado: (2020)

Standard dosing of enoxaparin versus unfractionated heparin in critically ill patient with COVID-19: a multicenter propensity-score matched study
por: Al Sulaiman, Khalid, et al.
Publicado: (2022)

A Prospective Pilot Trial to Assess the Efficacy of Argatroban (Argatra(®)) in Critically Ill Patients with Heparin Resistance †
por: Bachler, Mirjam, et al.
Publicado: (2020)

Anti-PF4/heparin antibodies associated with repeated hemofiltration-filter clotting: a retrospective study
por: Lasocki, Sigismond, et al.
Publicado: (2008)

Alternative diagnosis to heparin-induced thrombocytopenia in two critically ill patients despite a positive PF4/heparin-antibody test
por: Hron, Gregor, et al.
Publicado: (2013)

Heparin-Induced Thrombocytopenia in Healthy Individuals with Continuous Heparin Infusion
por: Williams, Jonathan S., et al.
Publicado: (2018)

Fondaparinux in a critically Ill patient with heparin-induced thrombocytopenia: A case report
por: He, Yumiao, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_plngu1of9ak1efladg8gqk91js